Doubled drug substance capacity at Alvotech's Reykjavik, Iceland, site aims to secure steady US supply of the Humira biosimilar Simlandi.
|Articles|March 17, 2020
BPSA Summit Postponed for Fall 2020 After COVID-19 Outbreak
Author(s)BioPharm International Editors
The decision comes after a state-of-emergency was declared in Washington, DC, due to the ongoing outbreak of COVID-19.
Advertisement
On March 16, 2020, Kevin Ott, director of the Bio-Process Systems Alliance (BPSA) announced in an email to BPSA members and contacts that the BPSA Summit scheduled for July 15–17, 2020 in Washington, DC, will be postponed for a later date in fall 2020. The decision comes after a state-of-emergency was declared in Washington, DC, due to the ongoing outbreak of COVID-19.
“The decision to postpone our 10th Anniversary BPSA Summit was not an easy one to make, but we believe this is the proper course of action given the uncontrollable externalities we all face at the moment,” Ott said in the email. “We believe this to be a prudent business decision, and it is unanimously supported by the BPSA [e]xecutive [c]ommittee.”
Advertisement
Related to this article
The glucagon/GLP-1 dual agonist hit both weight loss endpoints in phase 3, though gastrointestinal discontinuations and competitor data temper the readout.
CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.
LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.
Novartis has secured an exclusive worldwide license to ABO2203, Abogen's investigational mRNA-encoded CD19xCD3 T-cell engager designed to produce the bispecific inside the body to reset B cells in autoimmune disease. The agreement also includes options on other programs built on Abogen's RNA platform.
The 15-month project could let living cell therapies ship and store at room temperature, cutting cold-chain costs that limit patient access.
A planned phase 3 trial will test the TROP2 ADC and PD-1/VEGF bispecific together in 1st-line triple-negative breast cancer.
Advertisement
Advertisement